Characterisation of gliclazide-PEG 8000 solid dispersions

Tropical Journal of Pharmaceutical Research

Volumn 8, Issue 5, 2009, Pages 417-424

  Biswal, S ^a   Sahoo, J ^a   Murthy, P N ^a  

^a ROYAL COLLEGE OF PHARMACY AND HEALTH SCIENCES   (India)

Author keywords

Dissolution; DSC; FT IR; Gliclazide; PEG 8000; Solid dispersion; Solubility; X ray diffraction

Indexed keywords

CHLORIDE; GLICLAZIDE; MACROGOL 6000; MACROGOL 8000;

AQUEOUS SOLUTION; ARTICLE; COMPARATIVE STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DISSOLUTION; DRUG SOLUBILITY; INFRARED SPECTROSCOPY; SOLUBILITY; SOLVENT EFFECT; X RAY DIFFRACTION;

EID: 70350490781     PISSN: 15965996     EISSN: 15969827     Source Type: Journal    
DOI: 10.4314/tjpr.v8i5.48085     Document Type: Article

References (23)

1. Reynolds JEF. (Ed.) Martindale. The Extra Pharmacopoiea XXX, 30th ed. The Pharmaceutical Press, London, 1993, pp 279-280.
2. Dollery SC. Therapeutic Drugs. Churchill Livingstone, London, 1991.
3. Harrower AD. Comparison of efficacy, secondary failure rate and complications of sulfonylurea. J Diabetes Complications, 1994; 8: 201-203.
4. Palmer KJ, Brogden RN. Gliclazide, an update of its pharmacological properties and therapeutic efficacy in NIDDM. Drugs, 1993; 46: 92-125.
5. Ford JL. The current status of solid dispersions. Pharm Acta Helv, 1986; 61: 69-88.
6. Özkan Y, Atay T, Díkman N, Isimer A, Aboul-Enein YH. Improvement of water solubility and in vitro dissolution rate of gliclazide by complexation with β-cyclodextrin. Pharm Acta Helv, 2000; 74: 365-370. (Pubitemid 30227321)
7. Winters S, York P, Timmins P. Solid state examination of a gliclazide: beta-cyclodextrin complex. Eur J Pharm Sc, 1997; 5: 209-214.
8. Sapkal NP, Kilor VA Bhusari KP, Daud AS. Evaluation of some methods for preparation of gliclazide- β-cyclodextrin inclusion complexes. Trop J Pharm Res, 2007; 6(4): 833-840.
9. Aggarwal S, Singh PN, Mishra B. Studies on solubility and hypoglycemic activity of gliclazide beta-cyclodextrin-hydroxypropylmethylcellulose complexes. Die Pharmazie, 2002; 57: 191-193.
10. Hong SS, Lee SH, Lee YJ, Chung SJ, Lee MH, Shim CK. Accelerated oral absorption of gliclazide in human subjects from a soft gelatin capsule containing a PEG 400 suspension of gliclazide. J Control Release, 1998; 51: 185-192.
11. Devalina L, Steven LK, Eric AS, James JF, Yihong Q, Weili W, William RP. Physicochemical considerations in the preparation of amorphous ritonavir-poly (ethylene glycol) 8000 solid dispersions. J Pharm Sci, 2001; 90(8):1015-1025.
12. Kashappa GHD, Hyun JP. Solubility studies on valdecoxib in the presence of carriers, cosolvents, and surfactants. Drug Dev Res, 2005; 62(1): 41-48.
13. Biswal S, Sahoo J, Murthy PN, Giradkar PR, Avari JG. Enhancement of dissolution rate of gliclazide using solid dispersions with polyethylene glycol 6000. AAPS PharmaSciTech, 2008; 9(2):563-570
14. Higuchi T, Connors K. Phase solubility techniques. Adv Ana Chem and Instrument, 1965; 4: 17-123.
15. Arias MJ, Gines JM, Moyano JR, Rabasco AM. Dissolution properties and in vivo behaviour of triamterene in solid dispersions with polyethylene glycols. Pharm Acta Helv, 1996; 71: 229-235.
16. Khan CA, Rhodes CT. The concept of dissolution efficiency. J Pharm Pharmacol, 1975; 27: 48-49.
17. Mura P, Manderioli A, Bramanti G, Ceccarelli L. Properties of solid dispersions of naproxen in various polyethylene glycols. Drug Devlop Ind Pharm, 1996; 22(9&10): 909-916. (Pubitemid 26373318)
18. Mooter GV, Augustijns P, Blaton N, Kinget R. Physico-chemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30. Int J Pharm, 1998; 164: 67-80. (Pubitemid 28160099)
19. Valizadeh H, Nokhodchi A, Qarakhani N, Zakeri-Milani P, Azarmi S, Hassanzadeh D, Lobenberg R. Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj 52, Lactose, Sorbitol, Dextrin, and Eudragit E100. Drug Devlop Ind Pharm, 2004; 30(3): 303-317.
20. Trapani G, Franco M, Latrofa A, Tullio C, Provenzano MR, Serra M, Muggironi M, Biggio G, Liso G. Dissolution properties and anticonvulsant activity of phenytoinpolyethylene glycol 6000 and polyvinylpyrrolidone K-30 solid dispersions. Int J Pharm, 2001; 225: 63-73. (Pubitemid 32728200)
21. Damian F, Blaton N, Naesens L, Balzarini J, Kinget R, Augustinjns P, Mooter GV. Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14. Eur J Pharm Sc, 2000; 10: 311-322.
22. Okonogi S, Yonemochi E, Oguchi T, Puttipipatkhachorn S, Yamamoto K. Enhanced dissolution of ursodeoxycholic acid from the solid dispersion. Drug Dev Ind Pharm, 1997b; 23: 1115-1121. (Pubitemid 27454103)
23. Yamashita K, Nakate T, Okimoto K, Ohike A, Tokunaga Y, Ibuki R, Higaki K, Kimura T. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm, 2003; 267: 79-91. (Pubitemid 37352952)